Vancouver, Canada

GenomeDx Biosciences

www.genomedx.com
Vancouver, Canada
SEARCH FILTERS
Time filter
Source Type

Title: Prospective study of biopsy Decipher scores in potential candidates for active surveillance Date: Saturday, May 13 (2:40 p.m. to 2:50 p.m. EST) Presentation Number: PD28-11 Room: BCEC - Room 205BC Presenter: Stacy Loeb, M.D., MSc, New York University Title: The Diverse Genomic Landscape of Low-risk Prostate Cancer Date: Monday, May 15 (10:15 a.m. to 10:20 a.m. EST) Presentation Number: PNFBA-09 Room: BCEC - Ballroom East Presenter: Matthew Cooperberg, M.D., M.P.H., University of California, San Francisco Title: Decipher Test Impacts Decision-Making among Patients Considering Adjuvant and Salvage Treatment following Radical Prostatectomy: Interim Results from the Multicenter Prospective PRO-IMPACT Study Date: Tuesday, May 16 (9:30 a.m. to 9:40 a.m. EST) Presentation Number: PD71-01 Room: BCEC - Room 162 Presenter: John L. Gore, M.D., M.S., University of Washington School of Medicine Title: Genomic Classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation in patients with prostate cancer: Development and internal validation of a multivariable prognostic model Date: Tuesday, May 16 (9:40 a.m. to 9:50 a.m. EST) Presentation Number: PD72-02 Room: BCEC - Room 205BC Presenter: Deepansh Dalela M.D., Henry Ford Health System Title: Molecular subtypes of muscle invasive bladder cancer are related to benefit from neoadjuvant chemotherapy: Development of a single sample patient assay Date: Saturday, May 13 (9:30 a.m. to 11:30 a.m. EST) Presentation Number: MP34-01 Room: BCEC - Room 253AB Presenter: Roland Seiler, M.D., University of British Columbia - Vancouver Title: Development and validation of novel genomic classifiers for prediction of adverse pathology after prostatectomy Date: Sunday, May 14 (1:00 p.m. to 3:00 p.m. EST) Presentation Number: MP57-18 Room: BCEC - Room 153 Presenter: Firas Abdollah, M.D., Henry Ford Health System Title: Assessing Decipher for predicting lymph node positive disease among men diagnosed with intermediate risk disease treated with prostatectomy and ePLND Date: Sunday, May 14 (3:30 p.m. to 5:30 p.m. EST) Presentation Number: MP64-12 Room: BCEC - Room 156 Presenter: John Davis, M.D., MD Anderson Cancer Center GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment. Derived from GRID, GenomeDx's Decipher Prostate and Bladder Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment. More information is available at www.deciphertest.com and www.deciphergrid.com GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy, Decipher Post-Op and Decipher Bladder are commercially available urologic cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomedxs-decipher-grid-and-decipher-tests-to-be-featured-in-multiple-abstracts-at-the-112th-american-urological-association-annual-meeting-300451255.html


"Although prognostic signatures have become widely established in prostate cancer research, the development of signatures that can predict response to individual therapies has been a difficult proposition," said Felix Feng, M.D., Associate Professor of Radiation Oncology and Urology at the University of California, San Francisco. "The clinical validation of the established breast cancer PAM50 signature for men with prostate cancer will help physicians to predict which patients are most likely to benefit from postoperative hormone therapy, allowing for personalized patient selection, potentially improving treatment outcomes and sparing many patients from unnecessary toxicity." The study included clinical and genomic data from 3,782 retrospectively and prospectively collected radical prostatectomy samples in the Decipher GRID, and found that the PAM50 signature had the ability to consistently classify prostate cancer into luminal A, luminal B, and basal-like subtypes. The study determined that luminal B prostate cancers are the most aggressive, with nearly half the patients experiencing metastasis at 10 years. Further, luminal B patients were found to respond better to post-operative ADT, suggesting that these patients should be prioritized for early initiation of hormone therapy. "Ultimately we envision the field moving towards a biomarker driven approach, whereby prognostic signatures are used to select patients with aggressive disease and predictive signatures are used to select specific therapies," said Doug Dolginow, M.D., chief executive officer of GenomeDx. "The combination of a genomic test such as Decipher and basal-luminal subtypes could allow for selection of patients who need postoperative ADT, improving the personalization of therapy for patients with prostate cancer." GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment. Derived from GRID, GenomeDx's Decipher Prostate and Bladder Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment. More information is available at www.deciphertest.com and www.deciphergrid.com GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy, Decipher Post-Op and Decipher Bladder are commercially available urologic cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California. UC Disclaimer  The information stated above was prepared by GenomeDX Biosciences and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of GenomeDX, or any of its products, by The Regents of the University of California, its officers, agents and employees. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomedxs-decipher-grid-aids-in-development-and-validation-of-molecular-subtypes-in-prostate-cancer-that-predict-response-to-hormone-therapy-300455996.html


Othman Laraki, chief executive officer and co-founder of Color, added, "GenomeDx's Decipher tests are an important tool for physicians and patients in the prostate cancer market, and we look forward to partnering with one of the scientific leaders in the field." About Color Color is a health technology service that offers physician-ordered genetic testing for hereditary cancer risk. The Color Test analyzes 30 genes that impact the most common hereditary cancers, including prostate, breast, ovarian, colorectal, pancreatic, uterine, melanoma, and stomach cancers. To learn more about Color, follow Color on Twitter @Color or Facebook at facebook.com/Color and visit color.com. About Decipher GRID® and Cancer Classifier Tests GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment. Derived from GRID, GenomeDx's Decipher Prostate and Bladder Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment. More information is available at www.deciphertest.com and www.deciphergrid.com About GenomeDx Biosciences GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy, Decipher Post-Op and Decipher Bladder are commercially available urologic cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomedx-and-color-collaborate-to-further-advance-precision-medicine-for-prostate-cancer-patients-and-their-families-300456575.html


A system for expression-based discrimination of distinct clinical disease states in prostate cancer is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated with recurrent or non-recurrent prostate cancer. The Prostate Cancer Prognostic system provides for sets of prostate cancer prognostic target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying prostate cancer tissue.


Patent
GenomeDx Biosciences | Date: 2015-10-29

A system for classifying thyroid nodule tissue as malignant or benign is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated to with either malignant or benign thyroid nodule disease. The thyroid classification system provides for sets of thyroid classifying target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying thyroid nodule tissue.


Patent
GenomeDx Biosciences | Date: 2013-09-06

Disclosed herein, in certain instances, are methods for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods for determining the treatment modality of a cancer in a subject. The methods comprise expression-based analysis of targets. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject.


Patent
GenomeDx Biosciences | Date: 2015-06-01

A system for classifying thyroid nodule tissue as malignant or benign is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated to with either malignant or benign thyroid nodule disease. The thyroid classification system provides for sets of thyroid classifying target sequences and further provides for combinations of polynucleotide probes and primers derived there from. These combinations of polynucleotide probes can be provided in solution or as an array. The combination of probes and the arrays can be used for diagnosis. The invention further provides further methods of classifying thyroid nodule tissue.


Patent
GenomeDx Biosciences | Date: 2014-03-11

Disclosed herein, in certain instances, are methods, systems and kits for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject. Further disclosed herein are classifiers for analyzing a cancer.


Patent
Mayo Foundation For Medical Education And Research and GenomeDx Biosciences | Date: 2013-08-16

Disclosed herein, in certain instances, are methods, systems and kits for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject.


Patent
University of British Columbia and GenomeDx Biosciences | Date: 2014-11-04

The present invention relates to methods, systems and kits for the diagnosis, prognosis and the determination of cancer progression of cancer in a subject. The invention also provides methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, certain instances, are probe sets for use in assessing a cancer status in a subject. Further disclosed herein are classifiers for analyzing a cancer, such as, for example, bladder cancer.

Loading GenomeDx Biosciences collaborators
Loading GenomeDx Biosciences collaborators